R. L. Wahl

Articles by R. L. Wahl

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data

ByJ. P. Leonard,A. D. Zelenetz,J. M. Vose,J. A. Radford,R. L. Wahl,A. Rohatiner,S. Kroll,R. Stagg,K. Nadeau,N. Valente,M. S. Kaminski

March 1st 2001

Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses

Latest Updated Articles

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data
March 1st 2001

R. L. Wahl

Articles by R. L. Wahl

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data

Latest Updated Articles

Trending on CancerNetwork

Reading a Changed Eye Examination and Impact on Therapy

Operationalizing the First Dose and Building the Oncology and Eye Care Partnership

FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

The Promise of CERVINO, MajesTEC-3, and EXCALIBER-RRMM in Multiple Myeloma